Citius Oncology(Ctor) Financials: Return On Assets Compared To Industry Average, Plus Other Key Ratios
Profitability Trend (Last 5 Years)
Profitability - return on assets
This chart shows the historical trend of return on assets for CTOR compared to its industry average over the recent years.
Ratio Definition and Interpretation
Name: Return on Assets (ROA)
Definition: ROA shows how efficiently the company turns everything it owns — its entire asset base — into net profit after all costs and taxes. A higher ROA means the business squeezes more profit from its assets. Lower ROA might reflect poor asset utilization or heavy reliance on expensive financing.
Interpretation:
• In '2022', CTOR's return on assets was -12.7%, representing returns generated from total assets. Industry average for Biotechnology: Pharmaceutical Preparations in '2022' stood at -58.4%.
• In '2023', CTOR's return on assets was -28.1%, representing returns generated from total assets. The decline from '2022' may indicate some operational or financial challenges. Industry average for Biotechnology: Pharmaceutical Preparations in '2023' stood at -66.2%. Industry average declined by 7.8% from previous year.
• In '2024', CTOR's return on assets was -32.0%, representing returns generated from total assets. The decline from '2023' may indicate some operational or financial challenges. Industry average for Biotechnology: Pharmaceutical Preparations in '2024' stood at -65.9%. Industry average increased by 0.3% compared to previous year.
Overall, CTOR's return on assets has been volatile but showed a downward trend over the past 3 years.
Formula: ROA = Net Income / Total Assets
Good Range: Commonly 5%-15%.